Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RONALD G NAHASS

Allopathic & Osteopathic Physicians Internal Medicine Infectious Disease

NPI
1023084928
CMS profile
136997
Location
HILLSBOROUGH, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$34,079.09

123 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 123 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RONALD G NAHASS

NPI 1023084928 · CMS profile ID 136997

Allopathic & Osteopathic Physicians / Internal Medicine / Infectious Disease

HILLSBOROUGH, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 123 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1023084928?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RONALD G NAHASS, NPI 1023084928, CMS profile ID 136997. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 123 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1023084928?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). RONALD G NAHASS, NPI 1023084928, CMS profile ID 136997. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 123 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1023084928?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
RONALD G NAHASS, NPI 1023084928, CMS profile ID 136997, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 123 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1023084928?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

123 matching records · $34,079.09 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 123 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 123.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $12.6107/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891229365 CMS
ViiV Healthcare Company $1,625.0007/26/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944124869 CMS
Gilead Sciences, Inc. $13.0207/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929510797 CMS
ABBVIE INC. $1,725.0007/18/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891229363 CMS
ABBVIE INC. $520.0007/14/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891229361 CMS
Gilead Sciences, Inc. $9.2007/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929510785 CMS
ViiV Healthcare Company $14.7707/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944124809 CMS
ViiV Healthcare Company $6.7007/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944124903 CMS
ViiV Healthcare Company $14.9607/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944124879 CMS
Janssen Biotech, Inc. $15.0007/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886182853 CMS
Gilead Sciences, Inc. $2,200.0007/01/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929437338 CMS
Gilead Sciences, Inc. $14.7507/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929510819 CMS
Gilead Sciences, Inc. $78.5106/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929510825 CMS
Janssen Products, LP $113.9606/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887109719 CMS
EMD Serono, Inc. $14.6706/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941529959 CMS
ViiV Healthcare Company $11.3406/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944124909 CMS
ABBVIE INC. $4,600.0006/15/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891229359 CMS
ABBVIE INC. $677.2006/11/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891229339 CMS
ABBVIE INC. $25.9406/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891229341 CMS
ABBVIE INC. $7.4906/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891229343 CMS
ABBVIE INC. $49.9706/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891229345 CMS
ABBVIE INC. $7.5006/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891229347 CMS
ABBVIE INC. $22.5206/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891229349 CMS
ABBVIE INC. $7.4906/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891229351 CMS
ABBVIE INC. $47.3106/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891229353 CMS
ABBVIE INC. $7.5006/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891229355 CMS
ABBVIE INC. $155.4306/11/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891229357 CMS
ABBVIE INC. $192.6606/10/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891229333 CMS
ABBVIE INC. $124.9906/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891229335 CMS
ABBVIE INC. $155.4306/10/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891229337 CMS
ViiV Healthcare Company $14.9106/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944124921 CMS
Merck Sharp & Dohme LLC $9.6206/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944187685 CMS
Gilead Sciences, Inc. $14.6806/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929510817 CMS
Theratechnologies Inc. $12.9506/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943967805 CMS
Melinta Therapeutics, LLC $14.3305/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 960315823 CMS
ABBVIE INC. $10.5405/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891229331 CMS
Janssen Biotech, Inc. $18.3405/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886182841 CMS
Gilead Sciences, Inc. $14.2805/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929510811 CMS
Gilead Sciences, Inc. $840.0005/09/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929437335 CMS
ViiV Healthcare Company $14.9705/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944124873 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $13.0504/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959970059 CMS
Janssen Biotech, Inc. $15.6904/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886182835 CMS
Gilead Sciences, Inc. $13.4004/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929510803 CMS
ViiV Healthcare Company $10.2004/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944124793 CMS
Merck Sharp & Dohme LLC $13.5904/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944142191 CMS
ViiV Healthcare Company $1,300.0004/05/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944124853 CMS
ViiV Healthcare Company $16.0204/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944124813 CMS
Gilead Sciences, Inc. $10.7903/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929510787 CMS
GlaxoSmithKline, LLC. $14.1703/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945138907 CMS
EMD Serono, Inc. $13.4503/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941501255 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $51,265.11 128
PY2020 $69,396.65 117
PY2021 $22,708.78 103
PY2022 $34,079.09 123
PY2023 $22,696.23 116
PY2024 $7,948.40 104
PY2025 $5,175.67 96

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $112,076.16 127
PY2024 Principal investigator $264,452.83 175
PY2023 Principal investigator $328,056.72 110
PY2022 Principal investigator $211,836.24 128
PY2021 Principal investigator $600,558.93 221
PY2020 Principal investigator $3,759,385.35 231
PY2019 Principal investigator $607,804.36 216

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

127 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 GlaxoSmithKline, LLC. $406.00 11/19/2025 Non-covered Recipient Entity
ID CARE INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A No dispute reported 06/30/2026 1192185870
Principal investigator 1 GlaxoSmithKline, LLC. $8,737.74 11/12/2025 Non-covered Recipient Entity
ID CARE INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A No dispute reported 06/30/2026 1192185849
Principal investigator 1 GlaxoSmithKline, LLC. $200.00 11/05/2025 Non-covered Recipient Entity
ID CARE INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A No dispute reported 06/30/2026 1192152935
Principal investigator 1 GlaxoSmithKline, LLC. $430.00 11/03/2025 Non-covered Recipient Entity
ID CARE INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A No dispute reported 06/30/2026 1192156310
Principal investigator 1 GlaxoSmithKline, LLC. $539.00 11/03/2025 Non-covered Recipient Entity
ID CARE INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A No dispute reported 06/30/2026 1192188713
Principal investigator 1 Insmed, Inc. $4,279.39 09/12/2025 Non-covered Recipient Entity
ID Care Inc
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189650780
Principal investigator 1 Insmed, Inc. $264.16 09/10/2025 Non-covered Recipient Entity
ID Care Inc
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189650776
Principal investigator 1 GlaxoSmithKline, LLC. $200.00 09/05/2025 Non-covered Recipient Entity
ID CARE INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A No dispute reported 06/30/2026 1192186784
Principal investigator 1 GlaxoSmithKline, LLC. $660.00 08/01/2025 Non-covered Recipient Entity
ID CARE INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A No dispute reported 06/30/2026 1192185857
Principal investigator 1 GlaxoSmithKline, LLC. $400.00 08/01/2025 Non-covered Recipient Entity
ID CARE INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A No dispute reported 06/30/2026 1192185861
Principal investigator 1 GlaxoSmithKline, LLC. $1,001.00 07/31/2025 Non-covered Recipient Entity
ID CARE INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A No dispute reported 06/30/2026 1192185877
Principal investigator 1 GlaxoSmithKline, LLC. $350.00 07/31/2025 Non-covered Recipient Entity
ID CARE INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A No dispute reported 06/30/2026 1192188699
Principal investigator 1 GlaxoSmithKline, LLC. $23,318.46 07/14/2025 Non-covered Recipient Entity
ID CARE INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A No dispute reported 06/30/2026 1192186757
Principal investigator 1 Insmed, Inc. $50.00 07/09/2025 Non-covered Recipient Entity
ID Care Inc
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189650778
Principal investigator 1 GlaxoSmithKline, LLC. $990.00 06/25/2025 Non-covered Recipient Entity
ID CARE INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A No dispute reported 06/30/2026 1192185845
Principal investigator 1 GlaxoSmithKline, LLC. $500.00 06/25/2025 Non-covered Recipient Entity
ID CARE INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A No dispute reported 06/30/2026 1192188704
Principal investigator 1 GlaxoSmithKline, LLC. $200.00 06/19/2025 Non-covered Recipient Entity
ID CARE INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A No dispute reported 06/30/2026 1192186761
Principal investigator 1 Insmed, Inc. $250.00 06/04/2025 Non-covered Recipient Entity
ID Care Inc
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189650766
Principal investigator 1 GlaxoSmithKline, LLC. $300.00 05/30/2025 Non-covered Recipient Entity
ID CARE INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A No dispute reported 06/30/2026 1192156356
Principal investigator 1 GlaxoSmithKline, LLC. $660.00 05/30/2025 Non-covered Recipient Entity
ID CARE INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A No dispute reported 06/30/2026 1192188549
Principal investigator 1 GlaxoSmithKline, LLC. $1,078.00 05/26/2025 Non-covered Recipient Entity
ID CARE INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A No dispute reported 06/30/2026 1192099033
Principal investigator 1 GlaxoSmithKline, LLC. $100.00 05/26/2025 Non-covered Recipient Entity
ID CARE INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A No dispute reported 06/30/2026 1192156318
Principal investigator 1 Janssen Research & Development, LLC $5,800.00 05/23/2025 Non-covered Recipient Entity
Id Care Infectious Disease
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175244787
Principal investigator 1 Insmed, Inc. $264.16 05/21/2025 Non-covered Recipient Entity
ID Care Inc
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189650764
Principal investigator 1 Insmed, Inc. $50.00 05/21/2025 Non-covered Recipient Entity
ID Care Inc
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189650768
Principal investigator 1 Insmed, Inc. $50.00 05/21/2025 Non-covered Recipient Entity
ID Care Inc
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189650770
Principal investigator 1 Insmed, Inc. $264.16 05/21/2025 Non-covered Recipient Entity
ID Care Inc
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189650772
Principal investigator 1 Insmed, Inc. $50.00 05/21/2025 Non-covered Recipient Entity
ID Care Inc
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189650774
Principal investigator 1 Janssen Research & Development, LLC $824.00 05/20/2025 Non-covered Recipient Entity
Id Care Infectious Disease
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175244636
Principal investigator 1 Janssen Research & Development, LLC $549.00 05/20/2025 Non-covered Recipient Entity
Id Care Infectious Disease
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175244821
Principal investigator 1 Janssen Research & Development, LLC $1,342.00 05/14/2025 Non-covered Recipient Entity
Id Care Infectious Disease
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175244838
Principal investigator 1 GlaxoSmithKline, LLC. $100.00 05/13/2025 Non-covered Recipient Entity
ID CARE INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A No dispute reported 06/30/2026 1192156335
Principal investigator 1 GlaxoSmithKline, LLC. $330.00 05/13/2025 Non-covered Recipient Entity
ID CARE INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A No dispute reported 06/30/2026 1192186776
Principal investigator 1 GlaxoSmithKline, LLC. $19,203.03 04/28/2025 Non-covered Recipient Entity
ID CARE INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A No dispute reported 06/30/2026 1192156348
Principal investigator 1 GlaxoSmithKline, LLC. $140.00 04/28/2025 Non-covered Recipient Entity
ID CARE INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A No dispute reported 06/30/2026 1192185874
Principal investigator 1 GlaxoSmithKline, LLC. $100.00 04/28/2025 Non-covered Recipient Entity
ID CARE INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A No dispute reported 06/30/2026 1192188554
Principal investigator 1 Janssen Research & Development, LLC $2,819.00 04/17/2025 Non-covered Recipient Entity
Id Care Infectious Disease
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175244669
Principal investigator 1 Janssen Research & Development, LLC $1,281.00 04/15/2025 Non-covered Recipient Entity
Id Care Infectious Disease
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175244718
Principal investigator 1 Janssen Research & Development, LLC $118.00 04/11/2025 Non-covered Recipient Entity
Id Care Infectious Disease
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175244644
Principal investigator 1 Janssen Research & Development, LLC $105.00 04/11/2025 Non-covered Recipient Entity
Id Care Infectious Disease
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175244796
Principal investigator 1 Janssen Research & Development, LLC $105.00 04/10/2025 Non-covered Recipient Entity
Id Care Infectious Disease
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175244686
Principal investigator 1 Janssen Research & Development, LLC $105.00 04/10/2025 Non-covered Recipient Entity
Id Care Infectious Disease
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175244757
Principal investigator 1 Janssen Research & Development, LLC $105.00 04/10/2025 Non-covered Recipient Entity
Id Care Infectious Disease
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175244830
Principal investigator 1 Janssen Research & Development, LLC $105.00 04/10/2025 Non-covered Recipient Entity
Id Care Infectious Disease
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175244846
Principal investigator 1 GlaxoSmithKline, LLC. $100.00 04/08/2025 Non-covered Recipient Entity
ID CARE INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A No dispute reported 06/30/2026 1192185853
Principal investigator 1 GlaxoSmithKline, LLC. $330.00 04/08/2025 Non-covered Recipient Entity
ID CARE INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A No dispute reported 06/30/2026 1192188558
Principal investigator 1 Insmed, Inc. $190.50 03/31/2025 Non-covered Recipient Entity
ID Care Inc
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189650700
Principal investigator 1 Insmed, Inc. $63.50 03/31/2025 Non-covered Recipient Entity
ID Care Inc
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189650702
Principal investigator 1 Insmed, Inc. $190.50 03/31/2025 Non-covered Recipient Entity
ID Care Inc
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189650704
Principal investigator 1 Insmed, Inc. $190.50 03/31/2025 Non-covered Recipient Entity
ID Care Inc
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189650706
Principal investigator 1 Insmed, Inc. $298.45 03/31/2025 Non-covered Recipient Entity
ID Care Inc
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189650708
Principal investigator 1 Insmed, Inc. $63.50 03/31/2025 Non-covered Recipient Entity
ID Care Inc
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189650710
Principal investigator 1 Insmed, Inc. $63.50 03/31/2025 Non-covered Recipient Entity
ID Care Inc
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189650712
Principal investigator 1 GlaxoSmithKline, LLC. $100.00 03/28/2025 Non-covered Recipient Entity
ID CARE INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A No dispute reported 06/30/2026 1192156314
Principal investigator 1 GlaxoSmithKline, LLC. $330.00 03/28/2025 Non-covered Recipient Entity
ID CARE INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A No dispute reported 06/30/2026 1192188542
Principal investigator 1 GlaxoSmithKline, LLC. $100.00 03/26/2025 Non-covered Recipient Entity
ID CARE INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A No dispute reported 06/30/2026 1192156361
Principal investigator 1 GlaxoSmithKline, LLC. $330.00 03/26/2025 Non-covered Recipient Entity
ID CARE INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A No dispute reported 06/30/2026 1192156368
Principal investigator 1 Janssen Research & Development, LLC $3,398.00 03/25/2025 Non-covered Recipient Entity
Id Care Infectious Disease
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175244733
Principal investigator 1 GlaxoSmithKline, LLC. $330.00 03/21/2025 Non-covered Recipient Entity
ID CARE INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A No dispute reported 06/30/2026 1192156352
Principal investigator 1 GlaxoSmithKline, LLC. $100.00 03/21/2025 Non-covered Recipient Entity
ID CARE INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A No dispute reported 06/30/2026 1192185865
Principal investigator 1 GlaxoSmithKline, LLC. $330.00 03/21/2025 Non-covered Recipient Entity
ID CARE INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A No dispute reported 06/30/2026 1192188566
Principal investigator 1 GlaxoSmithKline, LLC. $100.00 03/21/2025 Non-covered Recipient Entity
ID CARE INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A No dispute reported 06/30/2026 1192188709
Principal investigator 1 Janssen Research & Development, LLC $1,220.00 03/14/2025 Non-covered Recipient Entity
Id Care Infectious Disease
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175244778
Principal investigator 1 GlaxoSmithKline, LLC. $100.00 03/07/2025 Non-covered Recipient Entity
ID CARE INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A No dispute reported 06/30/2026 1192156364
Principal investigator 1 GlaxoSmithKline, LLC. $330.00 03/07/2025 Non-covered Recipient Entity
ID CARE INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A No dispute reported 06/30/2026 1192188570
Principal investigator 1 GlaxoSmithKline, LLC. $100.00 03/06/2025 Non-covered Recipient Entity
ID CARE INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A No dispute reported 06/30/2026 1192156331
Principal investigator 1 GlaxoSmithKline, LLC. $100.00 03/06/2025 Non-covered Recipient Entity
ID CARE INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A No dispute reported 06/30/2026 1192156371
Principal investigator 1 GlaxoSmithKline, LLC. $330.00 03/06/2025 Non-covered Recipient Entity
ID CARE INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A No dispute reported 06/30/2026 1192186765
Principal investigator 1 GlaxoSmithKline, LLC. $100.00 02/24/2025 Non-covered Recipient Entity
ID CARE INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A No dispute reported 06/30/2026 1192152930
Principal investigator 1 GlaxoSmithKline, LLC. $100.00 02/24/2025 Non-covered Recipient Entity
ID CARE INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A No dispute reported 06/30/2026 1192152940
Principal investigator 1 GlaxoSmithKline, LLC. $350.00 02/24/2025 Non-covered Recipient Entity
ID CARE INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A No dispute reported 06/30/2026 1192156327
Principal investigator 1 GlaxoSmithKline, LLC. $100.00 02/24/2025 Non-covered Recipient Entity
ID CARE INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A No dispute reported 06/30/2026 1192186769
Principal investigator 1 GlaxoSmithKline, LLC. $330.00 02/24/2025 Non-covered Recipient Entity
ID CARE INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A No dispute reported 06/30/2026 1192186772
Principal investigator 1 GlaxoSmithKline, LLC. $106.00 02/24/2025 Non-covered Recipient Entity
ID CARE INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A No dispute reported 06/30/2026 1192188562
Principal investigator 1 GlaxoSmithKline, LLC. $330.00 02/24/2025 Non-covered Recipient Entity
ID CARE INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A No dispute reported 06/30/2026 1192188723
Principal investigator 1 Insmed, Inc. $35.56 02/21/2025 Non-covered Recipient Entity
ID Care Inc
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189650742
Principal investigator 1 Insmed, Inc. $41.91 02/21/2025 Non-covered Recipient Entity
ID Care Inc
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189650744
Principal investigator 1 Insmed, Inc. $298.45 02/21/2025 Non-covered Recipient Entity
ID Care Inc
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189650746
Principal investigator 1 Insmed, Inc. $19.05 02/21/2025 Non-covered Recipient Entity
ID Care Inc
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189650748
Principal investigator 1 Insmed, Inc. $19.05 02/21/2025 Non-covered Recipient Entity
ID Care Inc
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189650750
Principal investigator 1 Insmed, Inc. $190.50 02/21/2025 Non-covered Recipient Entity
ID Care Inc
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189650752
Principal investigator 1 Insmed, Inc. $50.00 02/21/2025 Non-covered Recipient Entity
ID Care Inc
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189650754
Principal investigator 1 Insmed, Inc. $264.16 02/21/2025 Non-covered Recipient Entity
ID Care Inc
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189650756
Principal investigator 1 Insmed, Inc. $1,157.86 02/21/2025 Non-covered Recipient Entity
ID Care Inc
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189650758
Principal investigator 1 Insmed, Inc. $208.03 02/21/2025 Non-covered Recipient Entity
ID Care Inc
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189650760
Principal investigator 1 Insmed, Inc. $208.03 02/21/2025 Non-covered Recipient Entity
ID Care Inc
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189650762
Principal investigator 1 Janssen Research & Development, LLC $234.00 02/21/2025 Non-covered Recipient Entity
Id Care Infectious Disease
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175244694
Principal investigator 1 Janssen Research & Development, LLC $272.00 02/19/2025 Non-covered Recipient Entity
Id Care Infectious Disease
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175244749
Principal investigator 1 Janssen Research & Development, LLC $544.00 02/14/2025 Non-covered Recipient Entity
Id Care Infectious Disease
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175244675
Principal investigator 1 Insmed, Inc. $0.44 02/11/2025 Non-covered Recipient Entity
ID Care Inc
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189650692
Principal investigator 1 Insmed, Inc. $6,888.84 02/11/2025 Non-covered Recipient Entity
ID Care Inc
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189650694
Principal investigator 1 Insmed, Inc. $0.46 02/11/2025 Non-covered Recipient Entity
ID Care Inc
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189650696
Principal investigator 1 Insmed, Inc. $0.46 02/11/2025 Non-covered Recipient Entity
ID Care Inc
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189650698
Principal investigator 1 GlaxoSmithKline, LLC. $330.00 02/10/2025 Non-covered Recipient Entity
ID CARE INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A No dispute reported 06/30/2026 1192156322
Principal investigator 1 GlaxoSmithKline, LLC. $100.00 02/10/2025 Non-covered Recipient Entity
ID CARE INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A No dispute reported 06/30/2026 1192156339
Principal investigator 1 GlaxoSmithKline, LLC. $231.00 02/10/2025 Non-covered Recipient Entity
ID CARE INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A No dispute reported 06/30/2026 1192156343
Principal investigator 1 GlaxoSmithKline, LLC. $51.00 02/10/2025 Non-covered Recipient Entity
ID CARE INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A No dispute reported 06/30/2026 1192186780
Principal investigator 1 GlaxoSmithKline, LLC. $330.00 02/10/2025 Non-covered Recipient Entity
ID CARE INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A No dispute reported 06/30/2026 1192188689
Principal investigator 1 GlaxoSmithKline, LLC. $100.00 02/10/2025 Non-covered Recipient Entity
ID CARE INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A No dispute reported 06/30/2026 1192188719
Principal investigator 1 Janssen Research & Development, LLC $395.00 02/10/2025 Non-covered Recipient Entity
Id Care Infectious Disease
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175244660
Principal investigator 1 Janssen Research & Development, LLC $1,342.00 02/10/2025 Non-covered Recipient Entity
Id Care Infectious Disease
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175244701
Principal investigator 1 Janssen Research & Development, LLC $351.00 02/10/2025 Non-covered Recipient Entity
Id Care Infectious Disease
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175244708
Principal investigator 1 Janssen Research & Development, LLC $351.00 02/05/2025 Non-covered Recipient Entity
Id Care Infectious Disease
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175244741
Principal investigator 1 Janssen Research & Development, LLC $234.00 02/05/2025 Non-covered Recipient Entity
Id Care Infectious Disease
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175244764
Principal investigator 1 Janssen Research & Development, LLC $395.00 02/05/2025 Non-covered Recipient Entity
Id Care Infectious Disease
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175244851
Principal investigator 1 Theratechnologies Inc. $540.00 02/03/2025 Non-covered Recipient Entity
I.D. Care Associates, PA
A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes with and without Ibalizumab in a Real-World Setting: United States (PROMISE-US) No dispute reported 06/30/2026 1249666483
Principal investigator 1 GlaxoSmithKline, LLC. $2,478.96 01/31/2025 Non-covered Recipient Entity
ID CARE INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A No dispute reported 06/30/2026 1192188546
Principal investigator 1 Janssen Research & Development, LLC $285.00 01/29/2025 Non-covered Recipient Entity
Id Care Infectious Disease
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175244652
Principal investigator 1 Janssen Research & Development, LLC $395.00 01/29/2025 Non-covered Recipient Entity
Id Care Infectious Disease
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175244725
Principal investigator 1 GlaxoSmithKline, LLC. $469.00 01/28/2025 Non-covered Recipient Entity
ID CARE INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A No dispute reported 06/30/2026 1192188695
Principal investigator 1 Insmed, Inc. $50.00 01/24/2025 Non-covered Recipient Entity
ID Care Inc
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189650714
Principal investigator 1 Insmed, Inc. $264.16 01/24/2025 Non-covered Recipient Entity
ID Care Inc
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189650716
Principal investigator 1 Insmed, Inc. $50.00 01/24/2025 Non-covered Recipient Entity
ID Care Inc
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189650718
Principal investigator 1 Insmed, Inc. $264.16 01/24/2025 Non-covered Recipient Entity
ID Care Inc
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189650720
Principal investigator 1 Insmed, Inc. $264.16 01/24/2025 Non-covered Recipient Entity
ID Care Inc
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189650722
Principal investigator 1 Insmed, Inc. $264.16 01/24/2025 Non-covered Recipient Entity
ID Care Inc
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189650724
Principal investigator 1 Insmed, Inc. $264.16 01/24/2025 Non-covered Recipient Entity
ID Care Inc
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189650726
Principal investigator 1 Insmed, Inc. $264.16 01/24/2025 Non-covered Recipient Entity
ID Care Inc
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189650728
Principal investigator 1 Insmed, Inc. $264.16 01/24/2025 Non-covered Recipient Entity
ID Care Inc
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189650730
Principal investigator 1 Insmed, Inc. $264.16 01/24/2025 Non-covered Recipient Entity
ID Care Inc
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189650732
Principal investigator 1 Insmed, Inc. $35.56 01/24/2025 Non-covered Recipient Entity
ID Care Inc
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189650734
Principal investigator 1 Insmed, Inc. $41.91 01/24/2025 Non-covered Recipient Entity
ID Care Inc
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189650736
Principal investigator 1 Insmed, Inc. $19.05 01/24/2025 Non-covered Recipient Entity
ID Care Inc
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189650738
Principal investigator 1 Insmed, Inc. $19.05 01/24/2025 Non-covered Recipient Entity
ID Care Inc
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189650740
Principal investigator 1 Janssen Research & Development, LLC $395.00 01/22/2025 Non-covered Recipient Entity
Id Care Infectious Disease
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175244804
Principal investigator 1 Janssen Research & Development, LLC $234.00 01/17/2025 Non-covered Recipient Entity
Id Care Infectious Disease
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175244810
Principal investigator 1 Janssen Research & Development, LLC $1,380.00 01/03/2025 Non-covered Recipient Entity
Id Care Infectious Disease
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175244771

Ownership and Investment Interests

One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together

Program yearMeasureAmountRecords
PY2025 Amount invested $0.00 1
PY2025 Value of interest $51,000.00 1
PY2024 Amount invested $0.00 1
PY2024 Value of interest $51,000.00 1
PY2023 Amount invested $0.00 1
PY2023 Value of interest $51,000.00 1
PY2022 Amount invested $0.00 1
PY2022 Value of interest $50,690.00 1
PY2021 Amount invested $50,000.00 1
PY2021 Value of interest $50,000.00 1

Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.

Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.

Ownership and Investment Interests records

Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them

5 records · PY2021–2025

Ownership and Investment Interests records (CSV)

Program yearCompanyAmount invested Value of interestTerms of interestInterest held by Dispute statusPublishedRecord ID
PY2025 New Wave Endo-Surgical Corp. $0.00 $51,000.00 Investment in company stock Physician Covered Recipient No dispute reported 06/30/2026 1233746453
PY2024 New Wave Endo-Surgical Corp. $0.00 $51,000.00 Investment Physician Covered Recipient No dispute reported 06/30/2026 1145542158
PY2023 New Wave Endo-Surgical Corp. $0.00 $51,000.00 Equity investment Physician Covered Recipient No dispute reported 06/30/2026 1033813675
PY2022 New Wave Endo-Surgical Corp. $0.00 $50,690.00 n/a Physician Covered Recipient No dispute reported 06/30/2026 907505085
PY2021 New Wave Endo-Surgical Corp. $50,000.00 $50,000.00 none Physician Covered Recipient No dispute reported 06/30/2026 838207971